专题：Colorectal Cancer Treatments and Studies

This cluster of papers represents advancements in the research and treatment of colorectal cancer, focusing on topics such as the use of cetuximab and bevacizumab, the impact of KRAS and BRAF mutations, the efficacy of chemotherapy, and the development of molecular subtypes for precision medicine. It also explores the role of EGFR inhibitors and the molecular mechanisms underlying metastatic colorectal cancer.
最新文献
262P Real-world data on immune-related adverse events with neoadjuvant pembrolizumab in early triple-negative breast cancer at the Norfolk and Norwich University Hospital

article Full Text OpenAlex

Clinical application of trastuzumab and docetaxel in the chemotherapy of human epidermal growth factor receptor 2 positive breast cancer patients

article Full Text OpenAlex

Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials

article Full Text OpenAlex

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

article Full Text OpenAlex

Impact of Proton Pump Inhibitors on Osimertinib-Induced Cardiotoxicity in NSCLC Patients

article Full Text OpenAlex

Predictive Factors for Chemotherapy Response in Colorectal Liver Metastasis: A Retrospective Study Utilizing Next-Generation Sequencing

article Full Text OpenAlex

Acute Neurotoxicity as an Adverse Event after Oxaliplatine Therapy in Cancer Patients: A Case Report

article Full Text OpenAlex

Risk factors, prognostic factors, and nomograms for liver metastasis in stage Tis-T2 colorectal cancer patients from a population-based study

article Full Text OpenAlex

A Real-World Pharmacovigilance Analysis of Lorlatinib-Associated Metabolic Effects Using The FDA Adverse Events Reporting System (FAERS) Database From 2013 to 2024

article Full Text OpenAlex

Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events

article Full Text OpenAlex

近5年高被引文献
Global colorectal cancer burden in 2020 and projections to 2040

review Full Text OpenAlex 1780 FWCI77.892

Diagnosis and Treatment of Metastatic Colorectal Cancer

review Full Text OpenAlex 1746 FWCI54.157

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 1329 FWCI122.906

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

article Full Text OpenAlex 1076 FWCI222.754

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

article Full Text OpenAlex 956 FWCI144.059

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

article Full Text OpenAlex 886 FWCI77.78

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 753 FWCI159.932

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

article Full Text OpenAlex 653 FWCI97.016

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

article Full Text OpenAlex 650 FWCI88.553

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

article Full Text OpenAlex 624 FWCI121.158